Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series

Abstract

Arsenic trioxide, believed to be a carcinogen and a teratogen, has found its niche in the treatment of acute promyelocytic leukemia (APL). APL is a disease affecting young patients. Post-treatment fertility and outcome of pregnancy are always a concern in a disease with high cure rates. We report a case series of six patients who were treated successfully for APL with arsenic trioxide and who parented at least one healthy offspring after completing their treatment.

Keywords::

• Arsenic trioxide (ATO)
• acute promyelocytic leukemia (APL)
• fertility
• parenthood

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.